ClinicalTrials.gg
CompletedNCT05657184Updated Jul 8, 2024

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

A Phase 1 interventional study of REGEND001 in Idiopathic Pulmonary Fibrosis, sponsored by Regend Therapeutics. Completed at 3 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Regend Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2021, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
54th of 60
12 · median 83
Started
2021
with 9 others
Phase 1
20 of 67
5 open now
Registered
25th of 67
by date
Lead sponsor
3 of 67
Regend Therapeutics

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 54th largest by enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2021, is one of 20 in phase 1, and was the 25th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged between 50 to 75.
  • Diagnosis of IPF according to 2018 Idiopathic Pulmonary Fibrosis Diagnostic Guidelines.
  • Participants with 30%\~79% of the predicted value in diffusing capacity for carbon monoxide (DLCO) and more than 50% of the predicted value in forced vital capacity (FVC) in pulmonary function tests within 3 months before screening.
  • Participants with typical HRCT images of IPF in the past 12 months.
  • Participants tolerant to bronchofiberscopy.
  • Participants fully informed with the purpose, method and possible discomfort of the trial, agreeing to participate in the trial and signing the voluntarily.
  • Participants with good adherence, willing to take medication and regular follow-up examinations as required by the protocol.
  • Participants able to understand and cooperate with the completion of pulmonary function tests.

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot tolerate cell therapy.
  • Pregnant or lactating women.
  • Participants with syphilis or any of (HIV), virus (HBV), virus (HCV) positive antibody; of which stable HBV carriers after drug treatment and cured hepatitis C patients can be enrolled.
  • Participants with malignant tumors or a history of malignant tumors.
  • Participants with a history of long-term use of drugs known to cause pulmonary fibrosis, such as amiodarone before screening.
  • Participants with lung infections or other infections, including bacterial and viral infections, with requirement of intravenous medications before cell transplantation.
  • Participants with a history of invasive or noninvasive mechanical ventilation within 4 weeks.
  • Participants with any of the following lung diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, pneumoconiosis, etc.; lung cancer, bronchiolitis obliterans or other active lung disease; pneumonia currently or in the past 4 weeks; pneumonectomy previously.
  • Requirement of oxygen therapy for more than 15 hours per day.
  • Suffering from serious diseases of other system.
  • leukopenia or agranulocytosis of any cause; blood creatinine > 2.5 times the ; (ALT) and aspartate transaminase (AST) > 2.5 times the upper limit of normal in the laboratory tests.
  • Participants with a history of mental illness, suicide risk, epilepsy or other central nervous system disorders.
  • Severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or atrioventricular block of degree II or above, shown by 12-lead (ECG).
  • Participants with a history of abusing alcohol or illicit drug.
  • Participants allergic to cattle products.
  • Participants in other clinical trials in the past 3 months.
  • Participants with poor compliance and difficult to complete the trial.
  • Investigators, employees of research centers or family members of them (none of whom are suitable to participate in the trial to ensure the objectivity of the research);
  • Participants with a history of hospitalization owing to acute exacerbation of IPF or other respiratory diseases three or more times within the past year.
  • Participants who is taking or is goning to take nintedanib within a month.
  • Participants with other acquired or congenital immunodeficiency disorders, or with a history of organ transplantation or cell transplantation therapy.
  • Participants whose expected survival may be less than one year judged by the investigator.
  • Male participants of and female participants within childbearing age were reluctant to use effective from the time of signing the to 6 months after cell therapy.
  • Participants assessed to be inappropriate in this clinical trial by investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    REGEND001

    Transplantation of autologous airway basal cells

    Drug: REGEND001

Interventions

  • Transplantation of REGEND001 for dose escalation.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of the cell therapy-related adverse events (AEs)

    Dose escalation is based on incidence of cell therapy-related AEs. Severity of cell therapy-related adverse events (AEs) is evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Within 24 weeks after treatment

Secondary outcomes

  1. Incidence of complication related to bronchoscopy

    REGEND001 is given to subjects by bronchoscopy. Thus, incidence of complication related to bronchoscopy is adapted to assess the safety of the products.

    Time frame: Within 24 weeks after treatment

  2. Change in lung diffusing capacity for single-breath carbon monoxide (DLCO-sb) from baseline

    DLCO-sb is measured by the single-breath method. It is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

    Time frame: 4, 12 and 24 weeks after treatment

  3. Change in forced vital capacity (FVC) from baseline

    FVC indicates the volume of air that can forcibly be blown out after a full inspiration.

    Time frame: 4, 12 and 24 weeks after treatment

  4. Change in the ratio of diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline

    The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It is a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream. Since DLCO is affected by the amount of inhaled gas and lung volume, the alveolar ventilation is considered to exclude the effect of lung volume on diffusion volume in evaluating diffusion function.

    Time frame: 4, 12 and 24 weeks after treatment

  5. Change in 6-minute-walk test (6MWT) from baseline

    The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.

    Time frame: 4, 12 and 24 weeks after treatment

  6. Change in St. George's Respiratory Questionnaire (SGRQ) scale from baseline

    Quality of life was assessed by St. George's Respiratory Questionnaire (SGRQ) scale. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.

    Time frame: 4, 12 and 24 weeks after treatment

  7. Change in lung imags of high resolution computed tomography (HRCT) from baseline

    Lung images from HRCT will be analyzed to indicate the newly-derived pulmonary structure.

    Time frame: 24 weeks after treatment

  8. Acute exacerbation of idiopathic pulmonary fibrosis (IPF)

    Frequency and severity of acute exacerbation of IPF will be evaluated.

    Time frame: Within 24 weeks after treatment

  9. Change in blood routine from baseline

    Number of cases or participants with abnormal laboratory test results will be evaluated.

    Time frame: Within 24 weeks after treatment.

  10. Change in urine routine from baseline

    Number of cases or participants with abnormal laboratory test results will be evaluated.

    Time frame: Within 24 weeks after treatment.

  11. Change in blood biochemistry from baseline

    Number of cases or participants with abnormal laboratory test results will be evaluated.

    Time frame: Within 24 weeks after treatment

  12. Change in 12-lead Electrocardiogram (ECG) from baseline

    Number of cases or participants with abnormal results wil be evaluated

    Time frame: Within 24 weeks after treatment

  13. Change in carcinoembryonic antigen (CEA) from baseline

    CEA is a tumor marker used for early diagnosis of lung cancer.

    Time frame: 12 and 24 weeks after treatment

  14. Change in neuron-specific enolase (NSE) from baseline

    NSE is a tumor marker significantly elevated in small cell lung cancer.

    Time frame: 12 and 24 weeks after treatment

  15. Change in cytokeratin-19-fragment (CYFRA21-1) from baseline

    CYFRA21-1 is a tumor marker which has important value for the pathological classification and prognosis evaluation of lung cancer.

    Time frame: 12 and 24 weeks after treatment

  16. Change in squamous cell carcinoma antigen (SCC) from baseline

    SCC is a specific marker for lung squamous cell carcinoma. Tumor markers are monitored to assess the safety.

    Time frame: 12 and 24 weeks after treatment

07

Study locations

3 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2023, 22 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 22 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Dec 20, 2022
StartActual
Jul 19, 2021
Primary completionActual
Jun 9, 2023
CompletionActual
Jun 9, 2023
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05657184
Lead sponsor
Regend Therapeutics
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Jul 19, 2021
Primary completion
Jun 9, 2023
Completion
Jun 9, 2023
Last update
Jul 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: REGEND001

Start the discussion